Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Mallinckrodt
AstraZeneca
McKesson
Medtronic

Last Updated: May 24, 2022

ZOKINVY Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Zokinvy, and when can generic versions of Zokinvy launch?

Zokinvy is a drug marketed by Eiger Biopharms and is included in one NDA. There are two patents protecting this drug.

This drug has nine patent family members in six countries.

The generic ingredient in ZOKINVY is lonafarnib. Additional details are available on the lonafarnib profile page.

DrugPatentWatch® Generic Entry Outlook for Zokinvy

Zokinvy will be eligible for patent challenges on November 20, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 20, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Summary for ZOKINVY
International Patents:9
US Patents:2
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 65
Patent Applications: 2,320
What excipients (inactive ingredients) are in ZOKINVY?ZOKINVY excipients list
DailyMed Link:ZOKINVY at DailyMed
Drug patent expirations by year for ZOKINVY
DrugPatentWatch® Estimated Generic Entry Opportunity Date for ZOKINVY
Generic Entry Date for ZOKINVY*:
Constraining patent/regulatory exclusivity:
TREATMENT OF HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) AND PROGEROID LAMINOPATHIES
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for ZOKINVY

ZOKINVY is protected by two US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ZOKINVY is See Plans and Pricing.

This potential generic entry date is based on TREATMENT OF HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) AND PROGEROID LAMINOPATHIES.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting ZOKINVY

Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: REDUCING THE RISK OF MORTALITY IN HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS)

Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: REDUCING THE RISK OF MORTALITY IN HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS)

FDA Regulatory Exclusivity protecting ZOKINVY

TREATMENT OF HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) AND PROGEROID LAMINOPATHIES
Exclusivity Expiration: See Plans and Pricing

NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eiger Biopharms ZOKINVY lonafarnib CAPSULE;ORAL 213969-001 Nov 20, 2020 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Eiger Biopharms ZOKINVY lonafarnib CAPSULE;ORAL 213969-002 Nov 20, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Eiger Biopharms ZOKINVY lonafarnib CAPSULE;ORAL 213969-001 Nov 20, 2020 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Eiger Biopharms ZOKINVY lonafarnib CAPSULE;ORAL 213969-002 Nov 20, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Eiger Biopharms ZOKINVY lonafarnib CAPSULE;ORAL 213969-001 Nov 20, 2020 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Eiger Biopharms ZOKINVY lonafarnib CAPSULE;ORAL 213969-001 Nov 20, 2020 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Eiger Biopharms ZOKINVY lonafarnib CAPSULE;ORAL 213969-002 Nov 20, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ZOKINVY

See the table below for patents covering ZOKINVY around the world.

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2004035753 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2006081444 See Plans and Pricing
European Patent Office 1552020 GENE LMNA ET SON IMPLICATION DANS LE SYNDROME D'HUTCHINSON-GILFORD ET L'ARTERIOSCLEROSE (LMNA GENE AND ITS INVOLVEMENT IN HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) AND ARTERIOSCLEROSIS) See Plans and Pricing
Japan 4436800 See Plans and Pricing
European Patent Office 1853265 INHIBITEURS DE FARNESYL TRANSFERASE DESTINES A TRAITER LES LAMINOPATHIES, LE VIEILLISSEMENT CELLULAIRE ET L'ATHEROSCLEROSE (FARNESYLTRANSFERASE INHIBITORS FOR USE IN THE TREATMENT OF LAMINOPATHIES, CELLULAR AGING AND ATHEROSCLEROSIS) See Plans and Pricing
Australia 2003301446 LMNA GENE AND ITS INVOLVEMENT IN HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) AND ARTERIOSCLEROSIS See Plans and Pricing
Canada 2501464 GENE LMNA ET SON IMPLICATION DANS LE SYNDROME D'HUTCHINSON-GILFOR D ET L'ARTERIOSCLEROSE (LMNA GENE AND ITS INVOLVEMENT IN HUTCHINSON-GILFORD PROGERIASYNDROME (HGPS) AND ARTERIOSCLEROSIS) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Colorcon
Harvard Business School
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.